Gilead Sciences Shares Sold by Holocene Advisors

Institutional investor reduces stake in biopharmaceutical company

Mar. 16, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Holocene Advisors LP, an investment management firm, lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.8% in the third quarter, according to the company's recent SEC filing. Holocene Advisors now owns 2,617,172 shares of the biopharmaceutical company's stock, down from 5,426,971 shares previously.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can signal shifts in investor sentiment and market expectations.

The details

Holocene Advisors sold 2,809,799 shares of Gilead Sciences during the third quarter, reducing its stake in the company to 0.21% of the outstanding shares. The firm cited unspecified reasons for the reduction in its Gilead Sciences holdings.

  • Holocene Advisors lowered its Gilead Sciences holdings in the third quarter of 2026.

The players

Holocene Advisors LP

An investment management firm that previously held a significant stake in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Holocene Advisors' Gilead Sciences holdings suggests a potential shift in investor sentiment towards the biopharmaceutical company, though the specific reasons behind the move are not clear. Investors and analysts will likely monitor Gilead's performance and any further changes in institutional ownership to gauge the market's outlook on the company.